Suppr超能文献

4-氨基-6-芳基氨基嘧啶-5-甲醛腙作为有效的ErbB-2/EGFR双激酶抑制剂。

4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors.

作者信息

Xu Guozhang, Abad Marta C, Connolly Peter J, Neeper Michael P, Struble Geoffrey T, Springer Barry A, Emanuel Stuart L, Pandey Niranjan, Gruninger Robert H, Adams Mary, Moreno-Mazza Sandra, Fuentes-Pesquera Angel R, Middleton Steven A

机构信息

Johnson & Johnson Pharmaceutical Research and Development, Medicinal Chemistry, 8 Clarke Drive, Cranbury, NJ 08512, USA.

出版信息

Bioorg Med Chem Lett. 2008 Aug 15;18(16):4615-9. doi: 10.1016/j.bmcl.2008.07.020. Epub 2008 Jul 10.

Abstract

Members of a novel class of 4-amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones were identified as potent dual ErbB-2/EGFR kinase inhibitors using concept-guided design approach. These compounds inhibited the growth of ErbB-2 over-expressing human tumor cell lines (BT474, N87, and SK-BR-3) in vitro. Compound 15 emerged as a key lead and showed significant ability to inhibit growth factor-induced receptor phosphorylation in SK-BR-3 cells (IC(50)=54 nM) and cellular proliferation in vitro (IC(50)=14, 58, and 58 nM for BT474, N87, and SK-BR-3 respectively). The X-ray co-crystal structure of EGFR with a close analog (17) was determined and validated our design rationale.

摘要

使用概念引导设计方法,一类新型的4-氨基-6-芳基氨基嘧啶-5-甲醛腙被鉴定为有效的双ErbB-2/EGFR激酶抑制剂。这些化合物在体外抑制ErbB-2过表达的人肿瘤细胞系(BT474、N87和SK-BR-3)的生长。化合物15成为关键先导物,显示出显著抑制SK-BR-3细胞中生长因子诱导的受体磷酸化的能力(IC(50)=54 nM)以及体外细胞增殖能力(BT474、N87和SK-BR-3的IC(50)分别为14、58和58 nM)。确定了EGFR与一种类似物(17)的X射线共晶体结构,并验证了我们的设计原理。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验